| 1 |
35190375 | Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. | 2022 Feb |
1 |
| 2 |
33002289 | Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. | 2021 Feb |
1 |
| 3 |
34732786 | The chemotherapeutic drug carboplatin affects macrophage responses to LPS and LPS tolerance via epigenetic modifications. | 2021 Nov 3 |
1 |
| 4 |
31119730 | Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer. | 2020 Jan 15 |
3 |
| 5 |
31886905 | Mode of action of carboplatin via activating p53/miR-145 axis in head and neck cancers. | 2020 Dec |
5 |
| 6 |
31937750 | Long Non-Coding RNA (lncRNA) BMP/OP-Responsive Gene (BORG) Promotes Development of Chemoresistance of Colorectal Cancer Cells to Carboplatin. | 2020 Jan 15 |
1 |
| 7 |
32072678 | The combination of artesunate and carboplatin exerts a synergistic anti-tumour effect on non-small cell lung cancer. | 2020 Jun |
1 |
| 8 |
31322224 | Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin. | 2019 Sep |
2 |
| 9 |
31621389 | Overexpression of Long Noncoding RNA E2F-Mediated Cell Proliferation Enhancing Long Noncoding RNA Is Involved in the Development of Chemoresistance of Cancer Cells to Carboplatin in Ovarian Endometrioid Adenocarcinoma. | 2019 Nov |
1 |
| 10 |
29854627 | Neuro- and nephroprotective effect of grape seed proanthocyanidin extract against carboplatin and thalidomide through modulation of inflammation, tumor suppressor protein p53, neurotransmitters, oxidative stress and histology. | 2018 |
2 |
| 11 |
27611952 | Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. | 2016 Oct 18 |
1 |
| 12 |
27998224 | Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months. | 2016 Dec 20 |
1 |
| 13 |
25490861 | Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis. | 2015 Feb |
1 |
| 14 |
25658463 | WIP1 phosphatase as a potential therapeutic target in neuroblastoma. | 2015 |
1 |
| 15 |
26722257 | Expression of mutant p53 in oral squamous cell carcinoma is correlated with the effectiveness of intra-arterial chemotherapy. | 2015 Nov |
1 |
| 16 |
24333234 | Utilization of an ex vivo human placental perfusion model to predict potential fetal exposure to carboplatin during pregnancy. | 2014 Mar |
1 |
| 17 |
25426548 | Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells. | 2014 Nov 30 |
1 |
| 18 |
24601052 | In vitro chemosensitivity assay of ascites in epithelial ovarian cancer. | 2013 |
1 |
| 19 |
22763759 | Loss of TP53 expression in immortalized choroid plexus epithelial cells results in increased resistance to anticancer agents. | 2012 Sep |
1 |
| 20 |
21868512 | The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro. | 2011 Sep |
5 |
| 21 |
20096282 | Akt inhibitor enhances apoptotic effect of carboplatin on human epithelial ovarian carcinoma cell lines. | 2010 Apr 25 |
1 |
| 22 |
20180806 | Hyperthermia-associated carboplatin resistance: differential role of p53, HSF1 and Hsp70 in hepatoma cells. | 2010 May |
1 |
| 23 |
19887545 | Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. | 2009 Nov |
1 |
| 24 |
18690840 | FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer. | 2008 Aug |
1 |
| 25 |
17063488 | Gadd45alpha does not modulate the carboplatin or 5-fluorouracil-induced apoptosis in human papillomavirus-positive cells. | 2007 Apr 1 |
1 |
| 26 |
17146434 | Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. | 2007 May 24 |
1 |
| 27 |
17208232 | p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: a novel target of p53 in apoptosis. | 2007 Jan 23 |
7 |
| 28 |
16459017 | Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin. | 2006 Sep 28 |
1 |
| 29 |
15854392 | [Relationship between the acquired multi-drug resistance of human large cell lung cancer cell line NCI-H460 by cisplatin selection and p53 mutation]. | 2005 Feb |
1 |
| 30 |
15908516 | Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs. | 2005 Aug |
1 |
| 31 |
16200870 | [Correlation between p53 gene mutation and the expression of tumor drug resistance genes in lung cancer and its clinical significance]. | 2004 Oct |
1 |
| 32 |
12684687 | The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. | 2003 May |
1 |
| 33 |
11862428 | Drug resistance in malignant rhabdoid tumor cell lines. | 2002 Feb |
1 |
| 34 |
12168940 | Correlation of clinical outcome with p53 and p21 status in patients with advanced transitional-cell carcinoma treated with paclitaxel and carboplatin. | 2002 Mar-Apr |
2 |
| 35 |
12499281 | Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand. | 2002 Dec 15 |
3 |
| 36 |
11507071 | Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. | 2001 Aug 15 |
1 |
| 37 |
11595686 | Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. | 2001 Oct |
3 |
| 38 |
10190788 | Carboplatin and paclitaxel, alone and in combination: dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene. | 1999 Feb |
2 |
| 39 |
9664115 | The apoptotic effects of cisplatin and carboplatin in retinoblastoma Y79 cells. | 1998 Aug |
1 |
| 40 |
10328543 | Accumulation of class I mutant p53 and apoptosis induced by carboplatin in a human glioma cell line. | 1998 |
1 |
| 41 |
9061063 | Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a neoadjuvant carboplatin-based regimen (M-CAVI). | 1996 Nov-Dec |
1 |
| 42 |
9081399 | Ovarian cancer, from the laboratory to the clinic: challenges for the future. | 1996 Jan |
1 |